Repositorio Dspace

Dimethyl fumarate induced Wells syndrome. A case report

Mostrar el registro sencillo del ítem

dc.contributor.author Candeliere-Merlicco, Antonio
dc.contributor.author Villaverde-González, Ramón
dc.contributor.author Hidalgo-Pérez, Paloma-Victoria
dc.contributor.author Escobar-Arias, Fabio-Hugo
dc.contributor.author Aparicio-Castro, Eladio
dc.contributor.author Lastres-Arias, María-del-Carmen
dc.date.accessioned 2026-05-13T10:26:13Z
dc.date.available 2026-05-13T10:26:13Z
dc.date.issued 2023
dc.identifier.citation Candeliere Merlicco A, Villaverde González R, Hidalgo Pérez PV, Escobar Arias FH, Aparicio Castro E, Lastres Arias MDC. Síndrome de Wells secundario a dimetilfumarato. A propósito de un caso clínico. RevNeurol. 2023;76(10):337. doi:10.33588/rn.7610.2022323
dc.identifier.issn 0210-0010
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/26460
dc.description.abstract INTRODUCTION: Wells syndrome, also known as eosinophilic cellulitis, is a rare dermatosis with approximately 200 cases previously described in the literature. Here, we present a case of a patient with multiple sclerosis with Wells syndrome induced by dimethyl fumarate (DMF). CASE REPORT: A 41-year-old Caucasian woman was treated with DMF in July 2021. One week later, she experienced itching on her upper and lower right arm, followed by the appearance of erythematous plaques covered with vesicles. The complete blood count showed an increased eosinophil count of up to 2,000 µL. The histological images demonstrated dermal eosinophil infiltration concordant with Wells syndrome. The clinical course was benign, with complete resolution of the lesions and normalization of the eosinophil count within four weeks. Administration of corticosteroids was not necessary. CONCLUSIONS: Eosinophilia is rare in patients with multiple sclerosis treated with DMF and usually does not require dosage adjustments. Although clinical manifestations of eosinophilia in these patients are very rare, it is important for practitioners to recognize the symptoms. Many neuroleptic drugs can induce eosinophilia and systemic symptoms; therefore, physicians must be aware of the risks associated with DMF and neuroleptic drugs, particularly for quetiapine, which contains fumarate.
dc.language.iso eng
dc.publisher REVISTA DE NEUROLOGIA
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.subject.mesh Adult
dc.subject.mesh Cellulitis
dc.subject.mesh Dimethyl Fumarate/adverse effects
dc.subject.mesh Antipsychotic Agents/therapeutic use
dc.subject.mesh Eosinophilia/chemically induced/complications/diagnosis
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh Multiple Sclerosis/drug therapy/complications
dc.title Dimethyl fumarate induced Wells syndrome. A case report
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 37165530
dc.relation.publisherversion https://www.imrpress.com/journal/RN/76/10/10.33588/rn.7610.2022323
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.33588/rn.7610.2022323
dc.journal.title Revista de Neurología
dc.identifier.essn 1576-6578


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta